阿托伐他汀对高血压合并高脂血症者血脂及超敏C反应蛋白的影响

Influence of atorvastatin on blood lipids and high-sensitivity C-reactive protein in patients with hypertension and hyperlipidemia

目的分析探讨阿托伐他汀治疗高血压合并高脂血症患者疗效及其对血脂、超敏C反应蛋白(hs-CRP)的影响。方法将符合标准的高血压合并高脂血症96例患者按照单双号分为两组,每组各48例,即研究组和对照组。对照组应用氨氯地平片5 mg,每日1次。研究组在对照组的基础上加服阿托伐他汀10 mg,每日1次。两组疗程均为12周。分析两组治疗前后的收缩压(SBP)、舒张压(DBP)、血脂指标[(甘油三酯(TG)、血清胆固醇(TC)、脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)]变化和hs-CRP变化。结果 1两组治疗后血压均较治疗前显著降低,且研究组降低更明显,与对照组治疗后比较,差异具有统计学意义(P<0.05)。2对照组治疗前后血脂指标水平无显著改变,差异无统计学意义(P>0.05)。研究组患者治疗后TG、TC、LDL-C水平较治疗前明显降低,HDL-C水平较治疗前明显升高,差异均有统计学意义(P均<0.05)。3研究组治疗后hs-CRP显著降低,与对照组比较,差异具有统计学意义(P<0.05)。4两组均未见明显不良反应。结论在氨氯地平的基础上加用阿托伐他汀治疗高血压合并高脂血症时,在降压、降脂方面效果更显著,hs-CRP显著降低,安全性好,值得临床推广应用。

Objective To investigate the effects of atorvastatin on blood lipids and high - sensitivity C - reactive protein（hs - CRP）in patients with hypertension and hyperlipidemia. Methods Ninety - six hypertension patients with hyperlipidemia were randomly divided into two groups,48 patients in each group. The control group was treated with 5 mg of amlodipine,once daily. In addition to the treatment of the control group,the study group was given 10 mg of atorvastatin,once daily. The treatment lasted 12 weeks. Systolic blood pressure,diastolic blood pres-sure,serum lipids and hs - CRP were analyzed before and after treatment. Results ① Blood pressure was significantly reduced after treatment, and it was more obvious in study group when compared with the control group（ P 〈 0. 05）. ② The levels of TG,TC,and LDL - C in the control group did not significantly change after treatment（ P ﹥ 0. 05）. The levels of TG,TC and LDL - C were significantly decreased and HDL - C level significantly increased after treatment in study group（all P 〈 0. 05）. ③Hs - CRP level was significantly decreased after treatment in study group compared with the control group,the difference was statistically significant（ P 〈 0. 05）. ④No obvious adverse reactions were observed in both groups. Conclusion The combined use of amlodipine and atorvastatin was safe and can lower blood lipids,blood pressure and hs - CRP in pa-tients with hypertension and hyperlipidemia.